This company has been marked as potentially delisted and may not be actively trading.

Longview Acquisition Corp. II (LGV) Competitors

LGV vs. TMO, ISRG, EW, IDXX, and ALC

Should you be buying Longview Acquisition Corp. II stock or one of its competitors? The main competitors of Longview Acquisition Corp. II include Thermo Fisher Scientific (TMO), Intuitive Surgical (ISRG), Edwards Lifesciences (EW), IDEXX Laboratories (IDXX), and Alcon (ALC). These companies are all part of the "med instruments" industry.

How does Longview Acquisition Corp. II compare to Thermo Fisher Scientific?

Thermo Fisher Scientific (NYSE:TMO) and Longview Acquisition Corp. II (NYSE:LGV) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, profitability, analyst recommendations, institutional ownership, earnings, valuation and dividends.

: In the previous week, Thermo Fisher Scientific had 32 more articles in the media than Longview Acquisition Corp. II. MarketBeat recorded 32 mentions for Thermo Fisher Scientific and 0 mentions for Longview Acquisition Corp. II. Thermo Fisher Scientific's average media sentiment score of 1.26 beat Longview Acquisition Corp. II's score of 0.00 indicating that Thermo Fisher Scientific is being referred to more favorably in the media.
Company Overall Sentiment
Thermo Fisher Scientific Positive
Longview Acquisition Corp. II Neutral
: Thermo Fisher Scientific has a net margin of 15.15% compared to Longview Acquisition Corp. II's net margin of 0.00%. Thermo Fisher Scientific's return on equity of 16.86% beat Longview Acquisition Corp. II's return on equity.
Company Net Margins Return on Equity Return on Assets
Thermo Fisher Scientific 15.15% 16.86% 8.15%
Longview Acquisition Corp. II N/A N/A N/A
: Thermo Fisher Scientific has higher revenue and earnings than Longview Acquisition Corp. II.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Thermo Fisher Scientific $45.20B 3.86 $6.70B $18.19 25.80
Longview Acquisition Corp. II N/A N/A N/A N/A N/A
: Thermo Fisher Scientific currently has a consensus target price of $623.05, suggesting a potential upside of 32.74%. Given Thermo Fisher Scientific's stronger consensus rating and higher possible upside, equities research analysts clearly believe Thermo Fisher Scientific is more favorable than Longview Acquisition Corp. II.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Thermo Fisher Scientific
0 Sell rating(s)
2 Hold rating(s)

19 Buy rating(s)

2 Strong Buy rating(s)
3.00
Longview Acquisition Corp. II
0 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
: 89.2% of Thermo Fisher Scientific shares are owned by institutional investors. 0.3% of Thermo Fisher Scientific shares are owned by company insiders. Comparatively, 26.4% of Longview Acquisition Corp. II shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Company	Overall Sentiment
Thermo Fisher Scientific	Positive
Longview Acquisition Corp. II	Neutral

Company	Net Margins	Return on Equity	Return on Assets
Thermo Fisher Scientific	15.15%	16.86%	8.15%
Longview Acquisition Corp. II	N/A	N/A	N/A

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Thermo Fisher Scientific	$45.20B	3.86	$6.70B	$18.19	25.80
Longview Acquisition Corp. II	N/A	N/A	N/A	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Thermo Fisher Scientific	0 Sell rating(s)	2 Hold rating(s)	19 Buy rating(s)	2 Strong Buy rating(s)	3.00
Longview Acquisition Corp. II	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Thermo Fisher Scientific beats Longview Acquisition Corp. II on 11 of the 12 factors compared between the two stocks.

How does Longview Acquisition Corp. II compare to Intuitive Surgical?

Intuitive Surgical (NASDAQ:ISRG) and Longview Acquisition Corp. II (NYSE:LGV) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, media sentiment, profitability, earnings and valuation.

: Intuitive Surgical has a net margin of 28.15% compared to Longview Acquisition Corp. II's net margin of 0.00%. Intuitive Surgical's return on equity of 15.98% beat Longview Acquisition Corp. II's return on equity.
Company Net Margins Return on Equity Return on Assets
Intuitive Surgical 28.15% 15.98% 14.07%
Longview Acquisition Corp. II N/A N/A N/A
: In the previous week, Intuitive Surgical had 33 more articles in the media than Longview Acquisition Corp. II. MarketBeat recorded 33 mentions for Intuitive Surgical and 0 mentions for Longview Acquisition Corp. II. Intuitive Surgical's average media sentiment score of 1.35 beat Longview Acquisition Corp. II's score of 0.00 indicating that Intuitive Surgical is being referred to more favorably in the media.
Company Overall Sentiment
Intuitive Surgical Positive
Longview Acquisition Corp. II Neutral
: Intuitive Surgical has higher revenue and earnings than Longview Acquisition Corp. II.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Intuitive Surgical $10.06B 15.93 $2.86B $8.25 54.88
Longview Acquisition Corp. II N/A N/A N/A N/A N/A
: Intuitive Surgical currently has a consensus price target of $581.91, indicating a potential upside of 28.52%. Given Intuitive Surgical's stronger consensus rating and higher possible upside, equities analysts clearly believe Intuitive Surgical is more favorable than Longview Acquisition Corp. II.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Intuitive Surgical
1 Sell rating(s)
7 Hold rating(s)

18 Buy rating(s)

0 Strong Buy rating(s)
2.65
Longview Acquisition Corp. II
0 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
: 83.6% of Intuitive Surgical shares are owned by institutional investors. 0.6% of Intuitive Surgical shares are owned by company insiders. Comparatively, 26.4% of Longview Acquisition Corp. II shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Company	Net Margins	Return on Equity	Return on Assets
Intuitive Surgical	28.15%	15.98%	14.07%
Longview Acquisition Corp. II	N/A	N/A	N/A

Company	Overall Sentiment
Intuitive Surgical	Positive
Longview Acquisition Corp. II	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Intuitive Surgical	$10.06B	15.93	$2.86B	$8.25	54.88
Longview Acquisition Corp. II	N/A	N/A	N/A	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Intuitive Surgical	1 Sell rating(s)	7 Hold rating(s)	18 Buy rating(s)	0 Strong Buy rating(s)	2.65
Longview Acquisition Corp. II	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Intuitive Surgical beats Longview Acquisition Corp. II on 10 of the 11 factors compared between the two stocks.

How does Longview Acquisition Corp. II compare to Edwards Lifesciences?

Longview Acquisition Corp. II (NYSE:LGV) and Edwards Lifesciences (NYSE:EW) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, media sentiment, dividends, valuation, profitability, institutional ownership, earnings and analyst recommendations.

: In the previous week, Edwards Lifesciences had 21 more articles in the media than Longview Acquisition Corp. II. MarketBeat recorded 21 mentions for Edwards Lifesciences and 0 mentions for Longview Acquisition Corp. II. Edwards Lifesciences' average media sentiment score of 0.85 beat Longview Acquisition Corp. II's score of 0.00 indicating that Edwards Lifesciences is being referred to more favorably in the news media.
Company Overall Sentiment
Longview Acquisition Corp. II Neutral
Edwards Lifesciences Positive
: Edwards Lifesciences has a net margin of 17.39% compared to Longview Acquisition Corp. II's net margin of 0.00%. Edwards Lifesciences' return on equity of 15.17% beat Longview Acquisition Corp. II's return on equity.
Company Net Margins Return on Equity Return on Assets
Longview Acquisition Corp. II N/A N/A N/A
Edwards Lifesciences 17.39% 15.17% 11.68%
: Edwards Lifesciences has higher revenue and earnings than Longview Acquisition Corp. II.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Longview Acquisition Corp. II N/A N/A N/A N/A N/A
Edwards Lifesciences $6.07B 7.88 $1.07B $1.88 44.14
: Edwards Lifesciences has a consensus target price of $95.65, indicating a potential upside of 15.27%. Given Edwards Lifesciences' stronger consensus rating and higher possible upside, analysts clearly believe Edwards Lifesciences is more favorable than Longview Acquisition Corp. II.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Longview Acquisition Corp. II
0 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
Edwards Lifesciences
0 Sell rating(s)

9 Hold rating(s)

16 Buy rating(s)

3 Strong Buy rating(s)
2.79
: 79.5% of Edwards Lifesciences shares are owned by institutional investors. 26.4% of Longview Acquisition Corp. II shares are owned by insiders. Comparatively, 0.3% of Edwards Lifesciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Company	Overall Sentiment
Longview Acquisition Corp. II	Neutral
Edwards Lifesciences	Positive

Company	Net Margins	Return on Equity	Return on Assets
Longview Acquisition Corp. II	N/A	N/A	N/A
Edwards Lifesciences	17.39%	15.17%	11.68%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Longview Acquisition Corp. II	N/A	N/A	N/A	N/A	N/A
Edwards Lifesciences	$6.07B	7.88	$1.07B	$1.88	44.14

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Longview Acquisition Corp. II	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Edwards Lifesciences	0 Sell rating(s)	9 Hold rating(s)	16 Buy rating(s)	3 Strong Buy rating(s)	2.79

Summary

Edwards Lifesciences beats Longview Acquisition Corp. II on 11 of the 12 factors compared between the two stocks.

How does Longview Acquisition Corp. II compare to IDEXX Laboratories?

IDEXX Laboratories (NASDAQ:IDXX) and Longview Acquisition Corp. II (NYSE:LGV) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, risk, profitability, earnings, media sentiment, dividends, analyst recommendations and valuation.

: In the previous week, IDEXX Laboratories had 24 more articles in the media than Longview Acquisition Corp. II. MarketBeat recorded 24 mentions for IDEXX Laboratories and 0 mentions for Longview Acquisition Corp. II. IDEXX Laboratories' average media sentiment score of 0.90 beat Longview Acquisition Corp. II's score of 0.00 indicating that IDEXX Laboratories is being referred to more favorably in the media.
Company Overall Sentiment
IDEXX Laboratories Positive
Longview Acquisition Corp. II Neutral
: IDEXX Laboratories currently has a consensus target price of $751.00, indicating a potential upside of 31.90%. Given IDEXX Laboratories' stronger consensus rating and higher possible upside, analysts clearly believe IDEXX Laboratories is more favorable than Longview Acquisition Corp. II.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
IDEXX Laboratories
0 Sell rating(s)
4 Hold rating(s)

7 Buy rating(s)

0 Strong Buy rating(s)
2.64
Longview Acquisition Corp. II
0 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
: IDEXX Laboratories has higher revenue and earnings than Longview Acquisition Corp. II.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
IDEXX Laboratories $4.45B 10.17 $1.06B $13.58 41.93
Longview Acquisition Corp. II N/A N/A N/A N/A N/A
: 87.8% of IDEXX Laboratories shares are owned by institutional investors. 0.8% of IDEXX Laboratories shares are owned by company insiders. Comparatively, 26.4% of Longview Acquisition Corp. II shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
: IDEXX Laboratories has a net margin of 24.63% compared to Longview Acquisition Corp. II's net margin of 0.00%. IDEXX Laboratories' return on equity of 70.87% beat Longview Acquisition Corp. II's return on equity.
Company Net Margins Return on Equity Return on Assets
IDEXX Laboratories 24.63% 70.87% 32.56%
Longview Acquisition Corp. II N/A N/A N/A

Company	Overall Sentiment
IDEXX Laboratories	Positive
Longview Acquisition Corp. II	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IDEXX Laboratories	0 Sell rating(s)	4 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.64
Longview Acquisition Corp. II	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IDEXX Laboratories	$4.45B	10.17	$1.06B	$13.58	41.93
Longview Acquisition Corp. II	N/A	N/A	N/A	N/A	N/A

Company	Net Margins	Return on Equity	Return on Assets
IDEXX Laboratories	24.63%	70.87%	32.56%
Longview Acquisition Corp. II	N/A	N/A	N/A

Summary

IDEXX Laboratories beats Longview Acquisition Corp. II on 10 of the 11 factors compared between the two stocks.

How does Longview Acquisition Corp. II compare to Alcon?

Longview Acquisition Corp. II (NYSE:LGV) and Alcon (NYSE:ALC) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, profitability, valuation, dividends, earnings, analyst recommendations, institutional ownership and risk.

: Alcon has a consensus target price of $86.05, suggesting a potential upside of 34.59%. Given Alcon's stronger consensus rating and higher possible upside, analysts clearly believe Alcon is more favorable than Longview Acquisition Corp. II.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Longview Acquisition Corp. II
0 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
Alcon
1 Sell rating(s)

6 Hold rating(s)

11 Buy rating(s)

2 Strong Buy rating(s)
2.70
: Alcon has higher revenue and earnings than Longview Acquisition Corp. II.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Longview Acquisition Corp. II N/A N/A N/A N/A N/A
Alcon $10.40B 3.04 $980M $1.66 38.52
: In the previous week, Alcon had 19 more articles in the media than Longview Acquisition Corp. II. MarketBeat recorded 19 mentions for Alcon and 0 mentions for Longview Acquisition Corp. II. Alcon's average media sentiment score of 0.76 beat Longview Acquisition Corp. II's score of 0.00 indicating that Alcon is being referred to more favorably in the news media.
Company Overall Sentiment
Longview Acquisition Corp. II Neutral
Alcon Positive
: 53.9% of Alcon shares are owned by institutional investors. 26.4% of Longview Acquisition Corp. II shares are owned by insiders. Comparatively, 1.5% of Alcon shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
: Alcon has a net margin of 7.70% compared to Longview Acquisition Corp. II's net margin of 0.00%. Alcon's return on equity of 7.11% beat Longview Acquisition Corp. II's return on equity.
Company Net Margins Return on Equity Return on Assets
Longview Acquisition Corp. II N/A N/A N/A
Alcon 7.70% 7.11% 4.99%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Longview Acquisition Corp. II	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Alcon	1 Sell rating(s)	6 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	2.70

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Longview Acquisition Corp. II	N/A	N/A	N/A	N/A	N/A
Alcon	$10.40B	3.04	$980M	$1.66	38.52

Company	Overall Sentiment
Longview Acquisition Corp. II	Neutral
Alcon	Positive

Company	Net Margins	Return on Equity	Return on Assets
Longview Acquisition Corp. II	N/A	N/A	N/A
Alcon	7.70%	7.11%	4.99%

Summary

Alcon beats Longview Acquisition Corp. II on 11 of the 12 factors compared between the two stocks.

Get Longview Acquisition Corp. II News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LGV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LGV vs. The Competition

Export

Metric	Longview Acquisition Corp. II	MED INSTRUMENTS Industry	Medical Sector	NYSE Exchange
Market Cap	N/A	$7.05B	$6.23B	$22.94B
Dividend Yield	N/A	1.76%	2.74%	4.03%
P/E Ratio	N/A	29.98	28.55	28.47
Price / Sales	N/A	57.72	535.83	14.37
Price / Cash	N/A	24.89	43.35	25.32
Price / Book	N/A	7.04	9.96	4.59
Net Income	N/A	$158.34M	$3.54B	$1.07B

Longview Acquisition Corp. II Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LGV Longview Acquisition Corp. II	N/A	$10.09 flat	N/A	N/A	$0.00	N/A	N/A	3	High Trading Volume
TMO Thermo Fisher Scientific	4.8792 of 5 stars	$469.39 -2.0%	$623.05 +32.7%	+16.3%	$174.37B	$44.56B	25.80	125,000	Positive News
ISRG Intuitive Surgical	4.467 of 5 stars	$457.78 +0.0%	$581.91 +27.1%	-14.8%	$162.13B	$10.06B	55.49	17,021	Positive News
EW Edwards Lifesciences	4.1615 of 5 stars	$84.08 +0.7%	$95.65 +13.8%	+11.0%	$48.42B	$6.07B	44.72	16,000
IDXX IDEXX Laboratories	3.9913 of 5 stars	$567.46 +1.2%	$751.00 +32.3%	+22.3%	$45.07B	$4.30B	43.42	11,000	Earnings Report

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:LGV) was last updated on 5/7/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Longview Acquisition Corp. II (LGV) Competitors

LGV vs. TMO, ISRG, EW, IDXX, and ALC

How does Longview Acquisition Corp. II compare to Thermo Fisher Scientific?

Summary

How does Longview Acquisition Corp. II compare to Intuitive Surgical?

Summary

How does Longview Acquisition Corp. II compare to Edwards Lifesciences?

Summary

How does Longview Acquisition Corp. II compare to IDEXX Laboratories?

Summary

How does Longview Acquisition Corp. II compare to Alcon?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LGV vs. The Competition

Longview Acquisition Corp. II Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Longview Acquisition Corp. II (LGV) Competitors

LGV vs. TMO, ISRG, EW, IDXX, and ALC

How does Longview Acquisition Corp. II compare to Thermo Fisher Scientific?

Summary

How does Longview Acquisition Corp. II compare to Intuitive Surgical?

Summary

How does Longview Acquisition Corp. II compare to Edwards Lifesciences?

Summary

How does Longview Acquisition Corp. II compare to IDEXX Laboratories?

Summary

How does Longview Acquisition Corp. II compare to Alcon?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LGV vs. The Competition

Longview Acquisition Corp. II Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools